SCHEMBL6649755

SCHEMBL6649755

Cc1ccc(C(=O)Nc2ccc(OCCc3ccccn3)cc2)c(Cl)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.49
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
KDM4E B2RXH2 3/20 0.48
PKM P14618 2/20 0.48
MITF O75030 1/20 0.48
P2RX3 P56373 1/20 0.45
MAPT P10636 2/20 0.45
CNR1 P21554 1/20 0.43
MET P08581 1/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
HTT P42858 2/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
GRM4 Q14833 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6645978 0.87 HTR2C (0.48) PPARGKDM4ECNR1ALDH1A1NR3C1
SCHEMBL6645798 0.86 KMT2A (0.52) PPARGNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL6645905 0.86 RAB9A (0.44) PPARGNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL6645987 0.85 CNR1 (0.50) NPC1RAB9ASMN1; SMN2KDM4EMAPT
SCHEMBL6644545 0.85 CHRNB2 (0.46) NPC1RAB9ASMN1; SMN2MAPTHSD17B10
SCHEMBL6644225 0.84 KDM4E (0.44) NPC1RAB9ASMN1; SMN2KDM4EMAPT
SCHEMBL6645448 0.82 L3MBTL1 (0.55) PPARGNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL6644382 0.81 ALDH1A1 (0.46) PPARGNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL6644273 0.81 LMNA (0.41) NPC1RAB9ASMN1; SMN2KDM4EMAPT
SCHEMBL6646168 0.80 NR3C1 (0.41) NPC1RAB9ASMN1; SMN2KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR PPARG 427/4885NPC1 34/4885RAB9A 3028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.